Whalesbook
Zydus Lifesciences Surges to Record High on Strong Q4 Earnings
Zydus Lifesciences' stock price reached an all-time high of Rs 1,083, marking a 6.3% increase, driven by a robust fourth-quarter performance for fiscal year 2026. The company reported a consolidated net profit of Rs 1,272.5 crore, up 8.7% year-over-year, with revenues climbing 16% to Rs 7,587 crore. Growth was significantly fueled by the company's United States and MedTech segments.
Despite a Rs 397.5 crore one-time charge for a Mirabegron litigation settlement, the company showed strong operational resilience. Adjusted net profit saw a more significant 15% rise to Rs 1,592.9 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew 20%, improving the EBITDA margin by 110 basis points to 33.7%. Investor confidence was further supported by the board's approval of a Rs 1,100 crore share buyback program at Rs 1,150 per share and a 100% dividend for FY26.
Analyst Views Mixed Amid Growth Drivers and U.S. Market Concerns
Brokerage firms reacted positively to Zydus Lifesciences' financial results, offering varied perspectives. Nuvama upgraded its rating to 'HOLD' with a higher target price of Rs 1,050, citing revenue growth above 16% and a strong gross margin of 74%. Nuvama expects further margin improvement from specialty product scaling, MedTech integration, and biologics growth. However, the firm projects flat U.S. revenue for FY27 and FY28, with a rebound in the specialty segment anticipated in FY28.
Motilal Oswal maintained a 'Neutral' rating and increased its target price to Rs 1,080. This firm noted that growth in India and emerging markets is helping to offset a moderating U.S. business. Motilal Oswal forecasts double-digit revenue growth from India and emerging markets to balance U.S. and API sales. They have also raised FY27 and FY28 earnings estimates by 5% and 4% respectively. Zydus Lifesciences' market capitalization was around Rs 1.2 trillion as of Wednesday.
Potential Risks in the U.S. Market and Margin Sustainability
Despite the record share price and strong earnings, Zydus Lifesciences faces potential challenges. The anticipated slowdown in the U.S. market, a major revenue source, presents a significant risk. Nuvama's forecast of flat U.S. revenue for the next two fiscal years indicates potential difficulties in achieving substantial growth in this critical market. This reliance on a cooling market could lead to overvaluation if growth expectations are not met.
Furthermore, while margins have improved, maintaining this expansion amid industry competition and evolving pharmaceutical regulations requires careful observation. The one-time litigation settlement, though managed operationally, serves as a reminder of potential unforeseen liabilities that could impact profitability.